UCB Frustrated By FDA Failure To Inspect Facility For Psoriasis Drug
Delays Expected Approval Of Bimekizumab
The Belgian group is the latest to be hit by the FDA's difficulties in address the growing backlog of facility inspections, leaving bimekizumab in limbo in the US, despite having just been approved as Bimzelx in Europe.
